GlassScriptPhysician profile
Neil Singhania
NPI 1669535886
$25,519.55
in general payments reported to CMS, 2019-2025
40 companies · $6,180 in 2025
The $6,180 reported for 2025 was more than what 85% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,531 · 2020: $1,467 · 2021: $2,078 · 2022: $2,670 · 2023: $2,820 · 2024: $2,773 · 2025: $6,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,680 · Consulting Fee: $3,078 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,680.44 |
| Consulting Fee | $3,077.50 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $4,875.07 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Glaxosmithkline, LLC. | $4,528.55 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,411.59 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,993.50 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,882.38 | 2019-2025 | Dupixent |
| Kaleo, INC. | $946.35 | 2019-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $913.33 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $862.03 | 2020-2025 | Takhzyro, Cuvitru, Glassia |
| Genzyme Corporation | $639.23 | 2019-2025 | |
| Covis Pharma Gmbh | $631.28 | 2019-2023 | |
| Genentech USA, INC. | $597.57 | 2019-2025 | Xolair |
| Pfizer INC. | $595.08 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $363.68 | 2019-2022 | |
| Grifols USA, LLC | $349.15 | 2021-2025 | Xembify, Gamunex-C |
| Optinose US, INC. | $322.42 | 2019-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $291.27 | 2019-2023 | Cutaquig |
| Amgen INC. | $267.57 | 2021-2025 | Tezspire |
| Pharming Healthcare, INC. | $254.93 | 2019-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $252.49 | 2021-2025 | Orladeyo |
| Blueprint Medicines Corporation | $221.57 | 2023-2025 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $171.29 | 2020-2023 | |
| Leo Pharma INC. | $163.24 | 2022-2023 | Adbry |
| Ars Pharmaceuticals Operations, INC. | $141.30 | 2025 | Neffy |
| Alk-Abello, INC | $110.50 | 2019-2024 | Standardized Mite D. Farinae, Histamine Positive, Timothy, Standardized |
| Organon LLC | $100.34 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $95.46 | 2024-2025 | Zoryve |
| Incyte Corporation | $85.33 | 2021-2023 | Opzelura |
| Aimmune Therapeutics, INC. | $80.38 | 2022 | |
| Shire North American Group INC | $72.95 | 2019 | |
| Azurity Pharmaceuticals, INC. | $60.66 | 2025 | Alvesco |
| Hikma Pharmaceuticals USA | $48.63 | 2023-2024 | Ryaltris |
| Merck Sharp & Dohme LLC | $41.05 | 2021-2023 | |
| Biocryst Pharmaceuticals, INC. | $27.80 | 2020 | |
| Lilly USA, LLC | $23.03 | 2025 | Ebglyss, Taltz |
| Kedrion Biopharma, INC. | $22.35 | 2025 | Gammaked, Koate, Kedrab |
| Abbvie INC. | $17.48 | 2023 | Rinvoq |
| Phadia US INC. | $17.14 | 2023 | Immunocap |
| Genentech, INC. | $16.57 | 2024 | Xolair |
| Galderma Laboratories, L.P. | $13.56 | 2025 | Nemluvio |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Singhania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.